Azilsartan previne markerii patologiei Alzheimer prin modularea BDNF și PPARγ într-un model experimental murin

This preclinical study investigated azilsartan, an angiotensin receptor blocker, delivered intranasally in an aluminum chloride-induced mouse model of Alzheimer's disease. Results showed intranasal azilsartan improved cognitive performance, restored antioxidant enzyme levels, reduced neuroinflammation markers, and outperformed donepezil in behavioral testing—though these findings require human validation.